The M13-982 study investigated CLL patients with relapsed/refractory (R/R) disease and with 17p deletion, a small number of whom had previously received BTK inhibitors: 20% of the enrolled patients obtained MRD negativity in PB (35). The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.